Journal
JOURNAL OF PEDIATRICS
Volume 163, Issue 6, Pages 1716-1721Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jpeds.2013.07.010
Keywords
-
Categories
Funding
- Maternal and Child Health Bureau [H18 MC-00004-11]
- Health Resources and Services Administration, Department of Health and Human Services
Ask authors/readers for more resources
Objective To evaluate whether the arctic variant (c.1436C -> T) of carnitine palmitoyltransferase type 1A (CPT1A) is associated with a higher incidence of adverse health outcomes in Alaska Native infants and children. Study design We evaluated health measures from birth certificates (n = 605) and Alaska Medicaid billing claims (n = 427) collected from birth to 2.5 years of age for a cohort of Alaska Native infants with known CPT1A genotype. To account for geographic variations in gene distribution and other variables, data also were evaluated in cohorts. Results When analysis was restricted to residents of nonhub communities in Western and Northern Alaska, children homozygous for the arctic variant experienced more episodes of lower respiratory tract infection than did heterozygous or noncarrier children (5.5 vs 3.7, P = .067) and were more likely to have had otitis media (86% vs 69%, 95% CI 1.4-8.9). Associations were weaker for more homogeneous cohorts. Conclusions The association of the arctic variant of CPT1A with infectious disease outcomes in children between birth and 2.5 years of age suggests that this variant may play a role in the historically high incidence of these health outcomes among indigenous Arctic populations; further studies will need to assess if this association was confounded by other risk factors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available